published in this issue of the journal, Bernelot Moens and coworkers describe an interesting correlation between monocyte CCR2 expression and LDL-cholesterol in humans. 3 Hypercholesterolaemia is a well-understood risk factor for atherosclerosis. The proatherogenic effects arise when cholesterol accumulates in the subintima, which can lead to evolution of atherosclerotic plaques. The critical role lipids play in atherosclerosis has motivated work leading to the development of statins and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors that efficiently lower blood LDL-cholesterol levels. However, even patients with wellcontrolled LDL-cholesterol have a residual risk for ischaemic events, which might be ascribed to inflammation. 4 Monocytes and monocyte-derived macrophages are protagonists of inflammation in atherosclerosis, and have been linked to hypercholesterolaemia. Preclinical work established that inflammatory monocytes increase in mice with hypercholesterolaemia, 5, 6 that the cells' production occurs not only in bone marrow but also in extramedullary sites such as the spleen, 7 and that disrupted reverse cholesterol transport leads to increased monocyte production. 8 Monocytes rely on the chemokine receptor CCR2 to migrate to inflammatory sites (Figure 1) . First, the cells react to CCR2's cognate receptor, the chemokine MCP-1 (monocyte chemoattractant protein 1), to depart into bone marrow sinusoids, and thus leave haematopoietic tissue. This mechanism was first described in mice exposed to lipopolysaccharide, a component of the bacterial wall. 9 Once in circulation, inflammatory monocytes continue to rely on CCR2 for recruitment into plaques 10, 11 and ischaemic tissue. 12 Interestingly, even heterozygous CCR2 deficiency impairs monocyte migration towards MCP-1, indicating that smaller fluctuations of CCR2 may be functionally relevant. 13 The importance of CCR2 in ischaemic heart disease is illustrated by the profound reduction of atherosclerosis and ischaemic injury in mice with genetic CCR2 deletion. 10, 12 Therapeutic targeting of CCR2 likewise greatly reduced monocyte migration to inflamed atherosclerotic plaque and myocardium. 14 Bernelot Moens et al. examined CCR2 expression in 22 patients with familiar hypercholesterolaemia (FH) treated with a PCSK9 inhibitor, a recently established drug class that efficiently lowers LDLcholesterol via increasing availability of hepatocyte LDL receptors, thus enhancing liver clearance of LDL-cholesterol from blood. The authors examined monocyte phenotypes before and after a 24-week treatment course, a design that enables conclusions about a relationship of LDL-cholesterol to changes in monocyte phenotype. C-reactive protein blood levels were not altered by the treatment, indicating that PCSK9 inhibitor action, as expected, was focused on cholesterol metabolism. The patient cohort was also compared with 14 FH patients on statins and 18 healthy matched controls.
While the authors did not detect changes in total monocyte numbers or subsets between patient cohorts, they report increased CCR2 expression by the classical monocyte subset in FH patients when compared with healthy volunteers. CX3CR1, CD11b, and CD18 expression also increased. Even in this relatively small cohort, plasma LDL-cholesterol correlated closely with CCR2 expression. In vitro, monocytes from FH patients migrated better towards MCP-1 whereas monocytes harvested from FH patients had more lipid droplets, especially among CCR2 high monocytes. Cholesterol efflux regulatory proteins ABCA1 and ABCG1 were augmented in the monocytes of FH patients, perhaps as a consequence of the increased lipid load. The authors measured CCR2 expression on monocytes prior to and after treatment with PCSK9 inhibitors, which effectively reduced LDL-cholesterol. Interestingly, this treatment reduced monocyte CCR2 surface staining by 60%, which is probably a biologically significant decrease. For comparison, monocyte-targeted RNAi (RNA interference) reduced CCR2 levels in mice by 50%, which led to a drastic change in the migratory capabilities of monocytes. 14 Bernelot Moens et al. further observed an overall less inflammatory monocyte phenotype after the treatment course, with reduced tumour necrosis factor (TNF) and increased interleukin-10 (IL-10) production. The study reports that CCR2 expression on human monocytes correlates with plasma LDL-cholesterol, a finding that yet again links cholesterol metabolism with innate immunity. 5, 6, 15 The data presented here suggest that hypercholesterolaemia influences the human monocyte phenotype. The observed increase in CCR2 expression may aid the cells' capability to migrate to inflamed atherosclerotic plaques and ischaemic tissues. Conversely, LDL-cholesterol lowering may influence the monocyte phenotype, reducing its migratory activity. Thus, CCR2 may serve as a marker for the inflammatory monocyte state in humans. Perhaps more importantly, these data strengthen the idea that CCR2 should be targeted therapeutically, as neutralizing CCR2 might dampen monocyte migration to inflamed cardiovascular organs. Indeed, CCR2-neutralizing drugs are in the pharmaceutical pipelines, and have already been shown to be safe in volunteers. One such drug significantly reduced circulating monocyte levels, 16 indicating that CCR2 regulates monocyte bone marrow exit not only in mice but also in humans. Thus, it appears to be an opportune time to study CCR2 inhibition in humans with ischaemic heart disease, either in patients with inflamed atherosclerotic lesions or in those with acute myocardial infarction. That said, before larger outcome studies are conducted, careful inflammation imaging and monitoring of blood monocyte levels is required as an intermediate step, 18 The latter haematopoietic organ is of interest because CCR2 may regulate the migration of haematopoietic progenitors from the marrow to the spleen. 2 The study also raised a number of interesting questions: how precisely does LDL-cholesterol regulate CCR2 expression? Why was the overall monocyte number unchanged after lowering CCR2 expression with PCSK9 inhibition? One potential explanation could be that cholesterol-monocyte interaction occurs in blood, after the cells have already left the marrow. What other myeloid cell properties change in patients treated with cholesterol-lowering drugs? Figure 1 The chemokine receptor CCR2 regulates myeloid cell traffic. HSPC, haematopoietic stem and progenitor cells.
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